Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Depreciation & Amortization (CF) (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $91000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 139.47% to $91000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $366000.0 through Dec 2025, up 297.83% year-over-year, with the annual reading at $366000.0 for FY2025, 297.83% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $91000.0 at Day One Biopharmaceuticals, up from $90000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $94000.0 in Q1 2025, with the low at $6000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $34812.5, with a median of $15500.0 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) tumbled 69.44% in 2023, then skyrocketed 506.67% in 2025.
  • Over 4 years, Depreciation & Amortization (CF) stood at $15000.0 in 2022, then fell by 13.33% to $13000.0 in 2023, then soared by 192.31% to $38000.0 in 2024, then soared by 139.47% to $91000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $91000.0, $90000.0, and $91000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.